The FDA has approved a supplemental biologics license application for Xeomin as a first-line treatment for blepharospasm, according to a press release from Merz.
Xeomin (incobotulinumtoxinA) was first approved to treat blepharospasm in 2010.
A randomized, double-blind, placebo-controlled, phase 3 clinical trial of 61 patients showed treated subjects had a –1.2 improvement in blepharospasm severity subscore as measured on the Jankovic rating scale compared to placebo-treated subjects (P = .004).
“Merz is proud to offer a first-line treatment option for blepharospasm, a devastating
Uncategorized